Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (9644)	6/15/1998 2:13:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

DaiS, You are right saying that a rebound will take some time. I think that even with Viagra in foreign countries, Vivus can carve out a large enough niche to maintain profitability. The key now is for Vivus to move their butts in the new plant and get into foreign markets. Vivus is expecting approval in Canada in July. They will get a $2,000,000.00 milestone payment from Janssen when this occurs. I hope Janssen is ready to market the minute they get approval. If Vivus is smart enough to improve its marketing techniques in the US to get new scripts flowing and we see this materialize this summer, I think we should be OK. It doesn't matter what percentage of the ED market Vivus has so long as it has a big enough percentage to maintain earnings growth.

To: DaiS who wrote (9644)	6/15/1998 2:52:00 PM
From: Frostman	Read Replies (1) \| Respond to of 23519

Improved Viagra in the works. Can someone with a little science under their belt explain to me how a systemic drug can be altered to act faster, with fewer side effects? and ICOS? Frostman ********************************* June 15, 1998 Pfizer/Viagra -2: Aimed At Heading Off Competitors Dow Jones Newswires LONDON -- Pfizer Inc. (PFE) said Monday it's developing a new, improved version of blockbuster oral impotence drug, Viagra - a move it hopes will keep it one step ahead of potential competitors. Research now underway at the company's Sandwich, U.K. laboratories is aimed at creating "Viagra with a plus," according to Gill Samuels, director of science policy for Pfizer Ltd., the U.K. unit of Pfizer Inc. "Obviously we are aiming to stay on top," Samuels told Dow Jones Newswires in an interview. "There is some very promising stuff going on." Apart from working on a female version of Viagra, Samuels said, Pfizer also wants to reduce the drug's side effects and make it faster acting. Viagra has been known to cause headaches and can be dangerous if used by people on heart medication. It also takes about an hour for the drug to take effect. Since being launched in April, Viagra has become one of the biggest selling drugs in the world and captured more than 90% of the U.S. market for impotence. But its success has attracted the attention of competitors, several of which are said to be developing their own versions of the drug. The biggest immediate threat to Viagra's dominance, according to some, is Icos Corp.'s IC351, a product in Phase II trials that is said to have similar efficacy to Viagra but lack many of its side effects.